

Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
511 The Lysine Histone Methyltransferase Setd2 Is Required for Appropriate Immunoglobulin VDJ Recombination	S. Haihua Chu, PhD*	7:00 a.m.	San Diego Convention Center, Room 8
530 Prostaglandin E2 Stimulates CREB-Mediated Modification of Histone Variant Nucleosomes at Enhancers to Promote Hematopoietic Stem Cell Fate	Audrey Sporrij, MSc*	7:15 a.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 24
531 Dissecting the Regulation of Human Hematopoiesis at Single-Cell and Single-Variant Resolution	Erik L. Bao, BS*	7:30 a.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 24
532 Comprehensive Integrated Genomic Perturbations Reveal Molecular Mechanisms of Red Blood Cell Trait Associations	Yuxuan Wu, PhD*	7:45 a.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 24
592 Anti-Bcma BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment	Shih-Feng Cho, MD, PhD	7:45 a.m.	San Diego Convention Center, Ballroom 20D
587 Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)	Ishwarya Murali, PhD, BS	8:00 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 5
623 Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)	Fangxin Hong, PhD	8:00 a.m.	San Diego Convention Center, Room 24B
594 Identification of Alpha-Enolase (ENO1) as a Novel Immunometabolic Target in Multiple Myeloma	Arghya Ray, PhD	8:15 a.m.	San Diego Convention Center, Ballroom 20D
546 MLL-Menin Inhibition Reverses Pre-Leukemic Progenitor Self-Renewal Induced By NPM1 Mutations and Prevents AML Development	Hannah J. Uckelmann, PhD*	8:15 a.m.	San Diego Convention Center, Room 9
600 OP-106 Horizon - Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS	Paul Richardson, MD	8:15 a.m.	San Diego Convention Center, Room 6F
606 Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd	Tomohiro Kubo, MD, PhD	8:15 a.m.	Manchester Grand Hyatt San Diego, Grand Hall A
Relapsed CLL: Sequencing, Combinations, and Novel Agents	Jennifer R. Brown, MD, PhD	10:30 a.m. – 12:00 p.m.	San Diego Convention Center, Room 6A

Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
644 Congenital X-Linked Myelodysplasia with Tetraploidy Is Associated with De Novo Germline C-Terminal Mutation of SEPT6, a Septin Filament Protein	Raffaele Renella, MD, PhD*	10:45 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 2
668 Ikzf3-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes	Gregory Lazarian	10:45 a.m.	San Diego Convention Center, Room 28D
651 Dual Effects of BCOR-PRC1.1 Dependent Gene Regulation Mediate Cooperation of BCOR and TET2 Mutations in Myeloid Transformation	Eva Johanna Schaefer, MD	11:00 a.m.	San Diego Convention Center, Room 9
705 A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)	Matthew S. Davids, MD, MMSc	11:00 a.m.	Manchester Grand Hyatt San Diego, Grand Hall B
647 Therapeutic Targeting of Telomere Diseases Via Novel Small Molecule Modulators of Non-Coding RNA Biogenesis	Neha Nagpal, PhD*	11:30 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 2
678 Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence	Pei-Hsuan Chen, PhD	11:45 a.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 15
714 Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis	Kira O Bona, MD, MPH*	11:45 a.m.	San Diego Convention Center, Room 24B
Global Hematology Symposium	Leslie Kean, MD, PhD*	12:15 – 1:15 p.m.	San Diego Convention Center, Room 6E
Ernest Beutler Lecture and Prize: New Insights into Bone Marrow Failure Syndromes	Alan D. D'Andrea, MD	1:30 – 2:30 p.m.	San Diego Convention Center, Hall AB
751 Single Cell Resolution of Glucocorticoid Effects on Erythroid Progenitor Cells	Hojun Li, MD, PhD*	2:45 p.m.	Marriott Marquis San Diego Marina, Grand Ballroom 2
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough	Ann Mullally, MD	2:45 – 4:15 p.m.	San Diego Convention Center, Room 6A
748 Early Clonal Hematopoiesis Detected in Gata2 heterozygosity By Color-Barcoding of Hematopoietic Stem Cells in Zebrafish	Serine Avagyan, MD, PhD*	3:30 p.m.	San Diego Convention Center, Room 11B
796 Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome	Mikko Myllymaki, MD, PhD	3:30 p.m.	Manchester Grand Hyatt San Diego, Grand Hall A

Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
820 Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL)	Pavan Bachireddy, MD	3:30 p.m.	Manchester Grand Hyatt San Diego, Grand Hall D
821 Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data	Pavan Bachireddy, MD	3:45 p.m.	Manchester Grand Hyatt San Diego, Grand Hall D
749 The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome	Tarek H. Mouhieddine, MD	3:45 p.m.	San Diego Convention Center, Room 11B
815 A Pooled Analysis of Survival By Defibrotide Timing of Initiation in Adults with Venous Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) Following Hematopoietic Stem Cell Transplant (HSCT)	Paul Richardson, MD	3:45 p.m.	Manchester Grand Hyatt San Diego, Seaport Ballroom A,
804 Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma	Mark Bustoros, MD	4:00 p.m.	San Diego Convention Center, Room 6F
Special Symposium on ASH-Supported Researchers	Giada Bianchi, MD	4:30 – 6:00 p.m.	San Diego Convention Center, Room 28D
889 PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL	Kimberly Bodaar, MD*	4:30 p.m.	San Diego Convention Center, Room 29C
949 Discovery of a Novel Mechanism of Resistance to Thalidomide Derivatives	Adam S. Sperling, MD, PhD	4:30 p.m.	San Diego Convention Center, Ballroom 20D
973 Impact of Timing and Location of Goals of Care Discussions for Patients with Blood Cancers	Oreofe O. Odejide, MD, MPH	4:30 p.m.	San Diego Convention Center, Room 24B
891 Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias	Laura Hinze*	5:00 p.m.	San Diego Convention Center, Room 29C
940 STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia	Zuzana Tothova, MD, PhD	5:15 p.m.	Manchester Grand Hyatt San Diego, Grand Hall A
893 Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies	Romain Guieze, MD	5:30 p.m.	San Diego Convention Center, Room 29C

Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
852 Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia	Hanny Al-Samkari, MD	5:45 p.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 24
888 Bcor Mutations Cooperate with Tet2 Deficiency to Promote RAS Transformation of Mouse Hematopoietic Progenitors	Iman Fares, PhD	5:45 p.m.	San Diego Convention Center, Room 10
972 Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study	Gregory A. Abel, MD, MPH	5:45 p.m.	Manchester Grand Hyatt San Diego, Seaport Ballroom A
1023 Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients	Erica B. Esrick, MD*	6:45 p.m.	San Diego Convention Center, Room 6B
1007 Founding Precision Therapy in 1q-Amplified Multiple Myeloma	Romanos Sklavenitis-Pistofidis, MD	7:15 p.m.	San Diego Convention Center, Ballroom 20A